---
title: "NHS National Framework for Medical Retinal Vascular Treatments - 1 December 2025"
ocid: "ocds-h6vhtk-055064"
canonical_url: "https://d3tenders.com/contract/?ocid=ocds-h6vhtk-055064"
markdown_url: "https://d3tenders.com/contract/ocds-h6vhtk-055064.md"
json_url: "https://d3tenders.com/contract/ocds-h6vhtk-055064.json"
source: "Find A Tender Service"
current_stage: "Award"
buyer: "NHS ENGLAND"
published: "2025-10-06"
---

# NHS National Framework for Medical Retinal Vascular Treatments - 1 December 2025

Buyer: NHS ENGLAND  
Current stage: Award  
OCID: ocds-h6vhtk-055064

[View canonical contract page](https://d3tenders.com/contract/?ocid=ocds-h6vhtk-055064)  
[Download OCDS JSON](https://d3tenders.com/contract/ocds-h6vhtk-055064.json)

## Summary

NHS England has completed an open procurement procedure for the NHS National Framework for Medical Retinal Vascular Treatments, scheduled to start on 1 December 2025. This procurement falls under the pharmaceutical products industry category and covers various regions in the United Kingdom, including North and South England, Midlands and East, and London. The contract is structured as a framework agreement with no reopening of competition, allowing for extensions up to 24 months at the authority's discretion. The procurement stage is now complete, with contracts signed on 22 September 2025 and the award valued in substantial figures, demonstrating NHS England's significant investment in retinal vascular treatments.

This procurement presents notable opportunities for businesses, particularly those in the pharmaceutical sector offering licensed medical retinal vascular anti Veg-F and intravitreal corticosteroid medicines. The framework seeks treatments for conditions such as neovascular age-related macular degeneration and diabetic macular oedema. Large pharmaceutical companies such as Abbvie Ltd, Bayer Plc, and Novartis Pharmaceuticals UK Ltd, as well as SMEs like Orion Pharma (UK) Ltd and Outlook Therapeutics, have been successful suppliers. This range of awarded suppliers highlights the framework's potential for both large and small companies to engage, fostering business growth through stable and lucrative long-term contracts with NHS England. Businesses capable of supplying innovative and effective medical treatments will find significant opportunities in this procurement process.

## Notice

NHS National Framework for Medical Retinal Vascular Treatments - 1 December 2025 Offer reference number: CM/PHS/25/5728 Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum of 24 months. Potential periods of call-offs under the framework agreement: CM/PHS/25/5728/01 - National Framework for Medical Retinal Vascular Treatments: 7NAT (National) 01/12/2025 to 31/05/2027 (18 months) CM/PHS/25/5728/02 - Regional Framework for Medical Retinal Vascular Treatments aflibercept 2mg: NOFE: (North of England) 01/12/2025 to 31/05/2027 (18 months) SOFE: (South of England) 01/12/2025 to 31/05/2027 (18 months) MAE: (Midlands and East) 01/12/2025 to 31/05/2027 (18 months) LNW: (London) 01/12/2025 to 31/05/2027 (18 months) Published By: Medicines Procurement and Supply Chain - NHS Medicines Value & Access, NHS England Provision of Licensed Medical Retinal Vascular Anti Veg-F and Intravitreal Corticosteroid medicines used in medical retinal vascular services for the NHS in England. To include but not limited to aflibercept, bevacizumab, brolucizumab, intravitreal dexamethasone, intravitreal fluocinolone, faricimab and ranibizumab used in the treatment of; * neovascular (wet) age-related macular degeneration (AMD) * visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) * proliferative diabetic retinopathy (PDR) * visual impairment due to diabetic macular oedema (DME) * visual impairment due to diabetic macular oedema (DME) who are pseudophakic or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy * vision impairment associated with chronic diabetic macular oedema, (DME) * visual impairment due to myopic choroidal neovascularisation (myopic CNV) * retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 2+ or 3+) or AP-ROP (aggressive posterior ROP) disease * inflammation of the posterior segment of the eye presenting as non-infectious uveitis * prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye

## Key Details

| Field | Value |
| --- | --- |
| Publication source | Find A Tender Service |
| Latest notice | https://www.find-tender.service.gov.uk/Notice/062482-2025 |
| Notice type | UK7 - Contract Details Notice |
| Procurement type | Framework |
| Procurement category | Goods |
| Procurement method | Open |
| Procurement method details | Open procedure |
| Tender suitability | Not specified |
| Awardee scale | Large, SME |
| All stages | Award |

## Dates

| Field | Value |
| --- | --- |
| Publication date | 6 Oct 2025 |
| Submission deadline | Not specified |
| Future notice date | Not specified |
| Award date | 30 Jul 2025 |
| Contract period | 1 Dec 2025 - 31 May 2027 |
| Recurrence | Not specified |

## Values

| Field | Value |
| --- | --- |
| Tender value | Not specified |
| Lots value | Not specified |
| Awards value | £1,471,752,146 |
| Contracts value | £1,471,752,146 |

## Status

| Field | Value |
| --- | --- |
| Tender status | Complete |
| Lots status | Complete |
| Awards status | Active, Pending |
| Contracts status | Active |

## Buyer

| Field | Value |
| --- | --- |
| Main buyer | NHS ENGLAND |
| Locality | LEEDS |
| Post town | Leeds |
| Postcode | LS1 4AP |
| Country | England |
| ITL 1 | TLI London |
| ITL 2 | TLI4 Inner London - East |
| ITL 3 | TLI45 Lambeth |
| Local authority | Lambeth |
| Electoral ward | Waterloo & South Bank |
| Westminster constituency | Vauxhall and Camberwell Green |
| Delivery location | Not specified |

## Supplier

| Field | Value |
| --- | --- |
| Number of suppliers | 17 |
| Supplier names | ABBVIE; ALIMERA SCIENCES; BAYER; BAYER PUBLIC; BIOGEN; BIOGEN IDEC; BIOSIMILAR COLLABORATIONS IRELAND; CELLTRION HEALTHCARE UNITED KINGDOM; MDBIOLOGICS; NOVARTIS PHARMACEUTICALS; ORION PHARMA (UK; OUTLOOK THERAPEUTICS; ROCHE PRODUCTS; SANDOZ; TEVA; THORNTON & ROSS; THORNTON AND ROSS |

## CPV Codes

### Divisions

- 33 - Medical equipments, pharmaceuticals and personal care products

### Codes

- 33600000 - Pharmaceutical products

## Release History

- 6 Oct 2025 at 11:40 - Award - UK7 - Contract Details Notice - https://www.find-tender.service.gov.uk/Notice/062482-2025
- 1 Aug 2025 at 10:49 - Award - UK6 - Contract Award Notice - https://www.find-tender.service.gov.uk/Notice/045153-2025

## Documents

- https://www.find-tender.service.gov.uk/Notice/062482-2025
  6th October 2025 - Contract details notice on Find a Tender
- https://www.find-tender.service.gov.uk/Notice/045153-2025
  1st August 2025 - Contract award notice on Find a Tender
- https://www.find-tender.service.gov.uk/Notice/Attachment/A-5896
  Framework Agreement and Terms and Conditions - Lot 1
- https://www.find-tender.service.gov.uk/Notice/Attachment/A-5897
  Framework Agreement and Terms and Conditions - Lot 2

## Notice URLs

- http://www.abbvie.co.uk/
- http://www.advanzpharma.com
- http://www.alimerasciences.eu
- http://www.amgen.co.uk
- http://www.bayer.co.uk
- http://www.mdbiologics.co.uk
- http://www.orifarm.com
- http://www.orionpharma.co.uk
- http://www.sandoz.com
- http://www.tevauk.com
- https://outlooktherapeutics.com/
- https://www.biogen-uk-ie.com
- https://www.celltrionhealthcare.co.uk
- https://www.england.nhs.uk/
- https://www.legislation.gov.uk/ukpga/2023/54/contents
- https://www.novartis.com/uk-en/
- https://www.roche.co.uk/
- https://www.thorntonross.com/

## Provenance

This Markdown file is an alternate public rendering of the D3 Tenders contract record. The canonical page is https://d3tenders.com/contract/?ocid=ocds-h6vhtk-055064. The underlying structured data is available as OCDS JSON at https://d3tenders.com/contract/ocds-h6vhtk-055064.json.